Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1
| Autor: | Nicole E. B. Skinner, Julie A. Kirihara, Elizabeth R. Seaquist, Matthew S. Wroblewski, Gary L. Nelsestuen |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Gene isoform
medicine.medical_specialty Mass spectrometry business.industry Endocrinology Diabetes and Metabolism Brief Report Apolipoprotein C1 Lipid metabolism Bioinformatics medicine.disease Sitagliptin Phosphate Endocrinology Oral administration Internal medicine Sitagliptin Diabetes mellitus Internal Medicine medicine Truncation (statistics) business medicine.drug |
| Zdroj: | Diabetes Therapy |
| ISSN: | 1869-6953 |
| DOI: | 10.1007/s13300-015-0123-1 |
| Popis: | Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA. Electronic supplementary material The online version of this article (doi:10.1007/s13300-015-0123-1) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|